Xeris Biopharma Holdings, Inc. — Form 8-K Summary
Reporting dates: The report was filed March 10, 2022, covering events beginning March 8, 2022. It also furnished fourth-quarter and full-year 2021 results through Exhibit 99.1; the supplied filing text does not include the exhibit’s detailed financial results.
Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The filing primarily reports a new secured financing, repayment of prior debt, and the furnishing of 2021 results and business highlights.
Key Financial Metrics and Liquidity
- The new Credit Agreement provides an initial term loan of $100.0 million.
- The Company may draw up to an additional $50.0 million in delayed-draw term loans during the one-year period following closing, in no more than three drawings of at least $10.0 million each, subject to specified conditions and financial covenant compliance.
- Proceeds were used to repay the prior Amended and Restated Loan and Security Agreement in full, including a final payment of $45.8 million; remaining proceeds are available for general corporate purposes.
- The new loans bear floating interest at a rate generally equal to 9.0% plus the applicable benchmark-based amount, subject to the rate mechanics and prime-rate alternative described in the agreement.
- The loans are secured by a first-priority lien on substantially all Company and subsidiary assets, including intellectual property, subject to exceptions.
- The loans may not be re-borrowed after repayment. The filing text does not provide revenue, net income, cash flow, cash balance, or margin figures for 2021.
Material Changes Versus the Prior Comparable Period
- The Company replaced its prior secured financing with the Hayfin facility and repaid the former facility in full.
- The refinancing increased available committed term financing from the disclosed transaction perspective, providing $100.0 million initially and potential access to an additional $50.0 million.
- The lenders received warrants to purchase 1,315,789 common shares at an exercise price of $2.28 per share, potentially creating dilution.
Guidance, Outlook, Risks, and Unusual Items
- The Credit Agreement contains customary representations, events of default, and affirmative and negative covenants. Restrictions apply to additional indebtedness, liens, acquisitions, mergers, dividends, equity repurchases, investments, asset dispositions, and certain affiliate transactions, subject to exceptions.
- Voluntary prepayments may trigger an early-payment charge: a make-whole amount before the second anniversary; 5.0% between the second and third anniversaries; 3.0% between the third and fourth anniversaries; and no fee after the fourth anniversary.
- The agreement includes an event of default for a material adverse change, among other customary defaults.
- The filing does not provide specific operating guidance or a detailed management outlook. The supplied text references, but does not reproduce, the press releases containing 2021 results, business highlights, and commentary.
Important Facts for Investors to Verify
- Review Exhibit 99.1 for fourth-quarter and full-year 2021 revenue, profitability, cash flow, liquidity, margins, and operating guidance.
- Confirm the final principal amount drawn, interest-rate calculations, maturity date, amortization schedule, and covenant thresholds in the complete Credit Agreement.
- Assess the liquidity impact of the $45.8 million repayment and the Company’s intended use of remaining proceeds.
- Evaluate potential warrant dilution from 1,315,789 shares exercisable at $2.28 per share and the warrants’ anti-dilution protections.
- Review Exhibit 99.2 and the complete credit documents for additional financing terms, contingencies, and management commentary.